Popular Articles

A New Take On Growth Factor Signaling In Tamoxifen Resistance
Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.
buy viagra
VIMPAT (lacosamide) Significantly Improved Partial-onset Seizure Control, Increased Seizure Freedom Rates And Enhanced Patient Function
New pooled clinical data presented at the 28th International Epilepsy Congress (IEC) in Budapest, Hungary showed that VIMPAT® (lacosamide), a new antiepileptic drug (AED) with a novel mode of action,1,2 significantly improved seizure control, increased seizure freedom rates during the maintenance phase and enhanced quality of life and patient function, when used as adjunctive therapy in adult patients with uncontrolled partial-onset seizures.2,3
News of the day
Mental Health America Commends Inclusion Of Mental Health, Substance Use Coverage In Health Reform Legislation
Mental Health America today commended Senate and House health reform legislation for including mental health and substance use coverage in a benefit package.
Diagnostics

Identification Of One Gene That Contributes To Breast Cancer's Aggressive Behavior

Aggressive forms of cancer are often driven by the abnormal over-expression of cancer-promoting genes, also known as oncogenes. Studies at the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR) of Singapore, have identified a gene, known as RCP (or RAB11FIP1), that is frequently amplified and over-expressed in breast cancer and functionally contributes to aggressive breast cancer behaviour. The research findings are published in the July 20th online issue of Journal of Clinical Investigation (JCI). The GIS team, led by Lance Miller, Ph.D., and Bing Lim, Ph.D., initially discovered that RCP expression was positively correlated with cancer recurrence in a population of breast cancer patients. This suggested that RCP may be required by some tumours for growth and metastatic spread to other organs. When the researchers over-expressed RCP in non-cancerous breast cells, they found that RCP promotes migration, or cellular movement, which is a precursor to the ability of tumours to invade neighbouring tissues. However, breast cancer cells in which RCP is over-expressed take on a more aggressive behaviour, including faster proliferation, enhanced migration/invasion and anchorage-independent growth. The researchers also found that when the gene is silenced in breast cancer cells, the ability of the cells to form tumours and metastasize to other organs is greatly diminished. They also found that RCP can activate the potent oncogene, Ras, which is aberrantly activated by mutation in about 15% of all human cancers. "One objective in my laboratory is to discover new oncogenes that drive breast cancer progression so that we can devise therapeutic strategies for shutting these genes down," said Dr. Miller, now at Wake Forest University School of Medicine in North Carolina. "The involvement of RCP in breast cancer progression may have significant clinical ramifications, and we are now working towards a better understanding of its mechanism of action." Notes: The JCI article is titled, "RCP is a novel breast cancer promoting gene with Ras activating function." Authors: Jinqiu Zhang1,5,9, Xuejing Liu2,9, Arpita Datta2, Kunde Govindarajan3, Wai Leong Tam1, Jianyong Han1, Joshy George3,6, Christopher Wong2, Kalpana Ramnarayanan2, Tze Yoong Phua2, Wan Yee Leong2, Yang Sun Chan2, Nallasivam Palanisamy2,7, Edison Tak-Bun Liu2, Krishna Murthy Karuturi3, Bing Lim1,4,10 and Lance David Miller2,8,10 1 Stem Cell and Developmental Biology, Genome Institute of Singapore, Singapore 2 Cancer Biology and Pharmacology, Genome Institute of Singapore, Singapore 3 Computational and Mathematical Biology, Genome Institute of Singapore, Singapore 4 Center for Life Sciences, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA 5 Current address: Stem Cell Disease Models, Institute of Medical Biology, Singapore 6 Current address: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 7 Current address: Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI, USA 8 Current address: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA 9 These authors contributed equally to this work 10 Corresponding authors: Dr. Lance Miller at Wake Forest University School of Medicine, Winston Salem, NC, Dr. Bing Lim at Genome Institute of Singapore Cathy Yarbrough Agency for Science, Technology and Research (A*STAR), Singapore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):